Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
qilongtian
- Development stage
- Preclinical
- Lead developer
- Kunming Hospital of Chinese Medicine
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
七龙天胶囊（qilongtian）是一种正在中国申报注册的中药复方制剂。该药物目前处于技术审评阶段，由昆明市中医医院申报，尚未获得正式批准上市。公开信息未披露其具体成分、机制或适应症，但根据命名习惯和相关政策文件推测，属于传统中药创新制剂类别，可能用于呼吸系统疾病或肿瘤等领域[3]。详细的作用机制、主要成分及临床数据暂未公开。
- Brand names
- 七龙天胶囊
- Other names
- 七龙天胶囊qilongtian
02
Targets
JUN (Transcription factor Jun)STAT3 (Signal Transducer and Activator of Transcription 3)MMP9 (Matrix metalloproteinase-9)VEGFA (Vascular endothelial growth factor A)CASP3 (Caspase-3)
Beyond the preview
Go deeper on qilongtian.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on qilongtian.